Why the study?
Despite growing awareness and clinical data on cancer therapeutics-related cardiac dysfunction, the molecular mechanisms underlying the pathogenesis caused by individual drugs remain to be determined.
This review highlights the importance of elucidating pathogenic mechanisms and establishing diagnostic and therapeutic strategies for cancer therapeutics-related cardiac dysfunction.
Underscores gaps in cardio-oncology; leaves open mechanistic insights and targeted diagnostics/therapies for cancer therapy-related cardiac dysfunction.
Improvements in the long-term survival of cancer patients have led to growing awareness of the clinical importance of cancer therapeutics-related cardiac dysfunction (CTRCD), which can have a considerable effect on the prognosis and quality of life of cancer patients and survivors. Under such circumstances, onco-cardiology/cardio-oncology has emerged as a new discipline, with the aim of best managing cardiovascular complications, including CTRCD. Despite the recent accumulation of epidemiological and clinical information regarding CTRCD, the molecular mechanisms underlying the pathogenesis of CTRCD by individual drugs remain to be determined. To achieve the goal of preventing cardiovascular complications in cancer patients and survivors, it is important to elucidate the pathogenic mechanisms and to establish diagnostic strategies with risk prediction and mechanism- and evidence-based therapies against CTRCD.
No takes yet. Share an insight, caveat, or question.
Kadowaki et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: